Kytopen | LinkedIn (original) (raw)

Biotechnology Research

Cambridge, Massachusetts 4,579 followers

Open cells to new possibilities: Accelerating cell therapy processes from discovery through manufacturing with Flowfect®

About us

Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect® platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect Discover™, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect Discover™ with the Flowfect Tx™ large-scale delivery device in process development workflows, developers can now surmount manufacturing challenges during the discovery stage, fostering swifter and more cost-effective innovation.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Cambridge, Massachusetts

Type

Privately Held

Founded

2017

Specialties

Transfection, Immunotherapy, Cell engineering, Mechanical engineering, Genetic engineering, Mammalian cells, Manufacturing, Immunology, CRISPR, CAR T-cell, Drug Discovery, Cell Therapy, Gene Therapy, Stem Cells, Gene Editing, mRNA, RNP delivery, NK cells, CD34+ stem cells, T cells, Cas9, and Nonviral

Locations

Employees at Kytopen

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding